Last Price
2.19
Today's Change
-0.03 (1.35%)
Day's Change
2.12 - 2.26
Trading Volume
420,282
Market Cap
64 Million
Shares Outstanding
29 Million
Avg Volume
6,302,670
Avg Price (50 Days)
1.72
Avg Price (200 Days)
2.94
PE Ratio
-1.15
EPS
-1.90
Earnings Announcement
07-Nov-2024
Previous Close
2.22
Open
2.22
Day's Range
2.12 - 2.2597
Year Range
1.0 - 8.89
Trading Volume
420,282
1 Day Change
-1.35%
5 Day Change
-12.40%
1 Month Change
53.15%
3 Month Change
76.61%
6 Month Change
4.29%
Ytd Change
-70.08%
1 Year Change
-64.93%
3 Year Change
-89.92%
5 Year Change
-87.55%
10 Year Change
-87.55%
Max Change
-87.55%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.